Steve Kirsch and Experts Discuss Inpatient Off-Label Treatments: Fluvoxamine & Ivermectin

Steve Kirsch, a successful technology entrepreneur and businessman has become a force for the positive during the COVID-19 pandemic. Kirsch has not just advocated for generic, economical repurposed drug strategies to help save more lives, but also went a few steps further than most could ever conceive by investing extensively to launch the COVID-19 Early Treatment Fund (CETF). Recently CETF sponsored a series of presentations by scientists and researchers in the drug development field exploring the use of existing approved therapies (repurposed drugs) that show the potential for efficacy and safety targeting COVID-19. In this video Kirsch and team, including Dr. David Seftel discuss the mounting data for both ivermectin and fluvoxamine as potential low cost and highly available generic medicines targeting COVID-19. Follow the link for this compelling, informative and some might think provocatively intriguing discussion. Dr. Seftel’s observational study was showcased on CBS’ 60 Minutes.  Also learn about the compelling ivermectin data.